- PDAT clinical outcomes for infectious keratitis from
Brazil andMexico
Provectus entered into an exclusive worldwide license agreement with the
RB PDAT emerged under the leadership of
ARVO 2024 RB PDAT presentations included:
- Evaluating the Safety of Rose Bengal Photodynamic Therapy, Huang et al., BPEI (Poster no. B0448, Session: Cornea),
- Rose Bengal Photodynamic Antimicrobial Therapy as an Adjuvant Treatment for Infectious Keratitis, Eskenazi-Betech et al., Instituto de Oftalmologia Fundacion Conde de Valenciana IAP (
Mexico ) (B0338, Cornea), - Assessment of photosensitizer concentration with a Singlet Oxygen luminescence dosimeter for Photodynamic Antimicrobial Therapy, Carrera et al., BPEI (B0570, Cornea),
- Clinical outcome in patients with infectious keratitis treated with Rose Bengal Photodynamic Antimicrobial Therapy (RB-PDAT) at the
Federal University ofSao Paulo (UNIFESP), Tabuse et al., Universidade Federal deSão Paulo (Brazil ) (B0575, Cornea), - Enhanced Fungal Inhibition with High-Dose Rose Bengal Photodynamic Antimiocrobial Therapy, Merikansky et al., BPEI (B0580, Cornea),
- Inhibition of Fungal Isolates via Singlet Oxygen Generation from Erythrosin B and Rose Bengal Photodynamic Antimicrobial Therapy, Ahmed et al., BPEI (Paper no. 4917, Cornea),
- Arginine-Mediated Enhancement of Photodynamic Antimicrobial Therapy to Target the Oxygen-Independent Pathway,
Gonzalez et al., BPEI (B0005, Immunology/Microbiology), and - Preclinical/Poster: Exploring the Combination of Rose Bengal Photodynamic Antimicrobial Therapy and Existing Antifungals, Krishna et al., BPEI (B0010, Immunology/Microbiology).
RB PDAT is the subject of two international Phase 3 randomized controlled trials for acanthamoeba and fungal (NCT05110001) and bacterial (NCT06271772) keratitis, and has been used to treat infectious keratitis patients in four countries to date:
U.S. : BPEI (first clinical reporting:Naranjo et al. 2019),India :LV Prasad Eye Institute (Bagga et al. 2022) and Aravind Eye Care System (NCT05110001 data readout planned in Q4 2024),Brazil : Universidade Federal de São Paulo (ARVO 2024), andMexico : Instituto de Oftalmología FAP (ARVO 2024).
About
About Provectus
Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets.
Information about the Company’s clinical trials can be found at the
FORWARD-LOOKING STATEMENTS: The information provided in this press release may include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Such statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of Provectus’s drug agents and/or their uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and the Company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the
- The Company’s Annual Report on Form 10-K for the period ended
December 31, 2023 .
#####
Contact:
Chief Financial Officer
Phone: (866) 594-5999
Source:
2024 GlobeNewswire, Inc., source